Skip to main content

Table 4 Summary of participant cardiotoxicity risk factors

From: Cardiotoxicity and cardiovascular disease risk assessment for patients receiving breast cancer treatment

Characteristics (n = 36)

Participants n (%)

Age > 50 years

27 (76)

Cancer type

 Breast

22 (61.2)

 Breast left

2 (5.6)

 Carcinoma of breast (elective (L) mastectomy 4/8/15)

1 (2.8)

 Lower-inner quadrant of breast

1 (2.8)

 Malignant breast cancer

1 (2.8)

 Malignant neoplasm of breast

3 (8.3)

 Malignant neoplasm of upper-outer quadrant of breast

1 (2.8)

 Metastatic HER-2 pos breast cancer

1 (2.8)

 Palpable cancer right breast

1 (2.8)

 Missing

3 (8.3)

Chemotherapy

Mean number of chemotherapy cycles 4.9 (Median 3) Range (1–16)

Agent class

Mean Dose (mg)

n (%)

Alkylating agents

 Carboplatin

658

5 (13.8%)

 Cyclophosphamide

1073

20 (56%)

Anthracyclines

 Doxorubicin

110

11 (30%)

Antimetabolites

 Fluorouracil

996

6 (17%)

Mitotic Inhibitors

 Docetaxel

158

15 (42%)

 Paclitaxel

156

20 (56%)

Monoclonal Antibody

 Denosumab

120

1 (2%)

 Trastuzumab

493

13 (36%)

Baseline Cardiac Assessment

 Echocardiography

14 (38.9)

 Left Ventricular Ejection Fraction <45%

0 (0)

 Angiography

1 (2.8)

 Electrocardiogram

11 (30.6)

  1. Summary of cardiotoxicity risk factors